S5631
Silicon dioxide
~99%, 0.5-10 μm (approx. 80% between 1-5 μm)
Synonym(s):
Sand, white quartz, Quartz, Silicon dioxide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
SiO2
CAS Number:
Molecular Weight:
60.08
NACRES:
SB.52
PubChem Substance ID:
UNSPSC Code:
12352300
EC Number:
238-878-4
MDL number:
assay
~99%
Quality Level
form
powder
particle size
0.5-10 μm (approx. 80% between 1-5 μm)
SMILES string
O=[Si]=O
InChI
1S/O2Si/c1-3-2
InChI key
VYPSYNLAJGMNEJ-UHFFFAOYSA-N
Preparation Note
A naturally occurring microcrystalline silica which has been finely ground.
Other Notes
Historically called amorphous.
Still not finding the right product?
Explore all of our products under Silicon dioxide
signalword
Danger
hcodes
Hazard Classifications
STOT RE 1 Inhalation
target_organs
Lungs
Storage Class
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Shifeng Li et al.
Theranostics, 10(4), 1719-1732 (2020-02-12)
The purpose of this study was to determine the effects of Kinesin family member 3A (KIF3A) on primary cilia and myofibroblast differentiation during silicosis by regulating Sonic hedgehog (SHH) signalling. Methods: Changes in primary cilia during silicosis and myofibroblast differentiation
Alida Kent et al.
Journal of tropical medicine, 2013, 324140-324140 (2013-11-07)
Cutaneous leishmaniasis (CL) is an emerging disease in Suriname, with at least 200 cases per year. Little is known about the biology of CL in the country. The most important parasite species is Leishmania Viannia guyanensis, but possible vectors and
Outi Leppäranta et al.
American journal of respiratory cell and molecular biology, 48(4), 448-455 (2012-12-22)
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis and very few therapeutic options. On the molecular level, patients with IPF have increased amounts of the bone morphogenetic protein (BMP) inhibitor gremlin in their lungs, which